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Summary 14 
Aim: To evaluate whether Utipro®, a natural product approved to prevent 15 
urinary tract infections, protects intestinal epithelial cells from Escherichia coli 16 
adherence/intracellular invasion in vitro. Materials & methods: Caco-2 and 17 
CacoGobletTM cells were treated with Utipro® (1.5 to 10 mg/mL) or untreated 18 
(controls). E. coli adherence/intracellular invasion were evaluated by Trans-19 
Epithelial Electrical Resistance (TEER), Lucifer Yellow assay and microbial 20 
counts. Results: Utipro® was non-cytotoxic. Utipro® 5 and 10 mg/mL protected 21 
cell tight junctions (mean±SD TEER [Ω×cm2] 66.83±0.29 and 71.33±0.29, 22 
respectively), and protected cells from E. coli intracellular invasion (mean±SD 23 
reductions in total bacteria counts [Log10] 0.9±0.06 and 2.1±0.56, respectively). 24 
Conclusion: Results of our study indicates that Utipro® creates a protective 25 
physical barrier on intestinal epithelial cells in vitro which reduces the settling of 26 
E. coli reservoirs.These results constitute the first step for the demonstration of 27 
the efficacy of Utipro® to prevent urinary tract infections. Futher research is 28 
needed in in vivo models and clinical trials.  29 
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1. INTRODUCTION 34 
Currently, urinary tract infections (UTIs) are among the most frequent 35 
community-acquired infections worldwide [1], mainly affecting women, but also 36 
patients with catheters, diabetes, immunodeficiency syndromes, underlying 37 
urologic abnormalities, and children [2]. Although UTIs are usually mild, 38 
recurrent UTIs have detrimental effects on the quality of life (QoL) of patients 39 
and on healthcare systems [2−7]. 40 
UTIs are mainly caused by Gram-negative bacteria, such as Escherichia coli, 41 
Pseudomonas spp, Enterobacter spp, Klebsiella spp and Serratia spp, and by 42 
some Gram-positive pathogens, such as Enterococcus spp and Staphylococcus 43 
spp. The most relevant uropathogen is E. coli which is responsible for 80% of 44 
UTIs in women [8]. The E. coli phylogenetic groups B2 and D prevail in women 45 
with recurrent UTIs. E. coli B2 finds a niche reservoir in fecal flora from UTI 46 
patients and healthy individuals [9,10], although the factors that may promote 47 
urinary tract colonization and bacterial virulence are not completely known [10]. 48 
The prevalence of fecal E. coli resistant to antibiotics in patients with recurrent 49 
UTIs is higher than in healthy individuals, thus increasing the risk of UTIs in 50 
these patients [11]. Currently, trimethoprim-sulfamethoxazole, nitrofurantoin, 51 
and fosfomycin are first-line therapies for uncomplicated cystitis and 52 
fluoroquinolones and beta-lactams are considered second-line options [3,12]. 53 
Clinical studies show that antimicrobial treatments achieve high percentages of 54 
cure after 3-7 days [12]. However, rates of drug and multidrug resistant 55 
uropathogens have increased in recent years, making the selection of 56 
antimicrobial treatment options for patients with recurrent UTIs more difficult 57 
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[3,13]. In this scenario, treatment failure can negatively affect the QoL of 58 
patients with recurrent UTIs and can also cause a non-negligible cost for the 59 
healthcare system. 60 
Non-pharmacological oral supplements, including cranberry 61 
proanthocyanidins [14,15,16Howell 2002; Howell et al. 2010; Gupta et al. 2012] 62 
and probiotics [17], have been evaluated for the prevention of UTIs. Although it 63 
is recognized that more research is needed, the use of non-pharmacological 64 
products to prevent UTIs should be considered a useful and safe alternative to 65 
antibiotics in this era of increasing antibiotic resistance [17]. 66 
Utipro® (Novintethical Pharma SA, Pambio-Noranco, Lugano, Switzerland) is 67 
a non-pharmacological oral medical device which was approved recently for the 68 
prevention of UTIs. It contains gelatin-xyloglucan (a natural hemicellulose) as 69 
the main ingredient, along with other plant extracts. Xyloglucan belongs to a 70 
new class of products, defined as “mucosal protectors”, which form a bio-71 
protective film, restoring the physiological functions of the intestinal walls. 72 
Results of recent clinical studies have shown that the administration of 73 
xyloglucan is a fast, efficacious and safe option for the treatment of acute 74 
diarrhea [18]. 75 
The rationale for the potential preventive action of Utipro® in UTIs is based 76 
on the protective properties of xyloglucan in the intestine to avoid the adhesivity 77 
of E. coli in the “intestinal reservoir” [19], the first step of uropathogenic E. coli 78 
proliferation which is followed by bacterial migration from the intestinal tract to 79 
the perineal region and, therefore, to the urinary tract [20,21]. The fecal-80 
perineal-urethral mechanism indicates that E. coli strains residing in the rectal 81 
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flora serve as a reservoir for urinary tract infections, such as cystitis [20,21]. 82 
This mechanism is more frequent in women due to the shorter distance of the 83 
perineal region [10,20]. 84 
A reduction in the amount of E. coli settling in the intestinal mucosa 85 
reservoirs may prevent colonization of the perianal region and the urinary tract 86 
and reinfection by this microorganism. 87 
 88 
In this study, we investigated whether Utipro®, containing the film forming 89 
agent xyloglucan and gelatin, could protect intestinal epithelial cells from E. coli 90 
adherence and intracellular invasion in an in vitro model.  91 
 92 
 93 
2. MATERIALS AND METHODS 94 
2.1. Compound 95 
Utipro® powder contains a combination of gelatin and xyloglucan, extracted 96 
from the seeds of the tamarind tree (Tamarindus indica), Hibiscus sabdariffa, 97 
propolis, silicon dioxide, magnesium stearate and corn. The product was kindly 98 
provided by Novintethical Pharma SA and diluted in bicarbonate solution. 99 
2.2. Cells and reagents 100 
Caco-2 cells (ATCC HTB37) and CacoGobletTM (Avancell, Spain) were used 101 
for the intestinal mucosa model. Caco-2 cells were seeded at a density of 102 
1.5×105 cells/well on 0.4 µM PET transwell inserts (Millipore) in 12-well plates 103 
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and maintained for 21 days. Caco-2 cells became confluent at day 6 and 104 
reached steady state at day 10. Cellular differentiation was completed at day 105 
21. Microvilli and tight junctions were visible by microscopy during cellular 106 
differentiation. CacoGobletTM is a ready-to-use model for evaluating in vitro 107 
intestinal absorption. The kit provides a 21-day cell barrier formed by 108 
differentiated co-culture Caco-2 and human globet mucus-screening cells 109 
(HT29H and HT29-MTX) plated on HTS transwell permeable supports.  110 
In both cases, cells were maintained in DMEM medium with high glucose 111 
(Dulbecco’s modified Eagle medium, Lonza, Belgium) supplemented with 10% 112 
fetal bovine serum (FBS, Lonza, Belgium), 1% Non-Essential Amino Acid 113 
(NEAA, Lonza, Belgium), 4 mM glutamine (Lonza, Belgium), 10 mM hepes 114 
(Lonza, Belgium) and 1% penicillin-streptomycin (Lonza, Belgium), at 37ºC, 115 
95% humidity and 5% CO2. 116 
Other reagents used were phosphate buffer solution (PBS; Sigma), Trypsin 117 
EDTA (Lonza), HBSS (Sigma), Lucifer Yellow (Sigma), MES (Sigma), Calcium 118 
Chloride Dihydrate (Sigma), Magnesium Chloride Hexahydrate (Sigma), Triton 119 
X-100 (Sigma), and Thiazolyl Blue Tetrazolium Blue (3-(4, 5-dimethylthiazolyl-120 
2)-2,5-diphenyltetrazolium bromide [MTT]; Sigma). 121 
2.3. Cytotoxicity 122 
Utipro® cytotoxicity was assessed on Caco-2 cells by MTT assay. Firstly, 123 
product interference with MTT was tested. A total of 10 mg of Utipro® was 124 
incubated in the presence of MTT (0.5 g/mL) for 3 hours at 37°C, 95% humidity, 125 
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5% CO2. Formazan production was qualitatively monitored by direct observation 126 
of purple coloring. Non-interference was observed. 127 
Caco-2 cells were then cultured at 120,000 cells/well with either 10 mg/mL 128 
Utipro® powder or Utipro® dissolved in bicarbonate solution, in 96-well culture 129 
plates by triplicate and incubated for 4h at 37ºC, 95% humidity and 5% CO2. 130 
Untreated cells (0 mg/mL) were use as control. After incubation, cell culture 131 
medium was removed and replaced with 200 μL of MTT solution (0.5 mg/mL 132 
MTT) per well. Plates were incubated again for 3h then MTT solution was 133 
replaced with isopropanol (200 μL) and incubated for 10 minutes under 134 
agitation to dissolve the purple formazan produced by viable cells into a colored 135 
solution. Absorbance was read at 570 nm (Microplate Autoreader Infinite® M-136 
200, Tecan, Durham, NC). Absorbance values were normalized to viability 137 
percentage relative to the Utipro® untreated control cells. The cytotoxic effect of 138 
Utipro® concentration was considered acceptable when the viability value was 139 
higher than 50%. 140 
2.4. Evaluation of the properties of Utipro® to preserve tight junctions of 141 
mucosa epithelial cells 142 
The effects of Utipro® in preserving the tight junctions of epithelial cells were 143 
evaluated in CacoGobletTM cells using Trans-Epithelial Electrical Resistance 144 
(TEER). Cell monolayers were treated with 0, 1.5, 2.5, 5 or 10 mg/mL of Utipro® 145 
powder dissolved in bicarbonate solution, in triplicate, and incubated for 4h at 146 
37ºC and 5% CO2. Both untreated cell-monolayers and transwells with the filter 147 
insert without cells (0 mg/mL of Utipro®) were used as controls. 148 
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TEER was applied to measure the barrier integrity by placing the appropriate 149 
electrodes in the apical (AP) and basolateral (BL) positions according to the 150 
manual instructions (Millicell® ERS meter, Millipore, Bedford, MA, USA). TEER 151 
measurements were carried out just before the addition of Utipro® and after 4h 152 
of treatment. Final TEER values (Ω × cm2) of cell-monolayers were obtained 153 
after subtracting the TEER value produced by the filter insert without cells. 154 
2.5. Evaluation of the properties of Utipro® to preserve the paracellular 155 
flux 156 
The effects of Utipro® in preserving the paracellular flux within the mucosal 157 
barrier model were evaluated in CacoGobletTM cells by Lucifer Yellow (LY) 158 
assay. Cell monolayers were treated with 1.5, 2.5, or 5 mg/mL of Utipro® 159 
powder dissolved in bicarbonate solution, in triplicate, and incubated for 4h at 160 
37ºC and 5% CO2. Untreated cells were used as controls. 161 
LY assay was performed before and after treatment to measure the degree 162 
of porosity of intercellular tight junctions of epithelial cells. Briefly, 0.3 mL/well of 163 
LY (100 µM dissolved in HBSS-1% MES buffer) was applied in the AP 164 
compartment of the cell monolayer, and 0.75 mL of HBSS-Ca2+/Mg2+ was 165 
applied in the BL compartment. Cells were then incubated for 2h at 37°C, 95% 166 
humidity and 5% CO2. After incubation, the paracellular flux of LY from the AP 167 
to the BL compartment was measured by fluorescence (RFU) using 168 
spectrofluorimeter (Tecan Infinite M200) at 428 nm excitation and 535 nm 169 
emission. LY flux was calculated with the following formula: 170 
LY Flux = (RFUBL/RFUAP) × 100, 171 
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where RFUB are fluorescent units detected at the BL compartment and 172 
RFUAP are fluorescent units detected at the AP compartment. The apparent 173 
permeability (PAPP, cm/sec) was calculated with the following formula: 174 
PAPP = (BL concentration/AP concentration) × (BL volume/Area × time). 175 
To estimate LY concentration in the AP and BL compartments, a standard 176 
curve was prepared using 2 fold increasing concentrations of LY (0.0 μM to 177 
200.0 μM) in a 96-well plate (100 μL, in triplicate). Acceptance criteria were: 178 
expected LY flow in untreated cell-monolayer lower than 10%, and expected 179 
PAPP coefficient less than 2.3×106 cm/sec (internal controls). 180 
2.6. Evaluation of the protective properties of Utipro® against E. coli 181 
invasion of intestinal epithelial cells 182 
The effects of Utipro® against E. coli invasion of CacoGobletTM cells were 183 
evaluated by inoculating 1×107 cfu/mL of E. coli (ATCC 8739) in each well. 184 
Previously, the optimal time period for E. coli adsorption was assessed at 1, 3, 6 185 
and 15h. Subsequently, 1h of adsorption time was chosen (data not shown). 186 
CacoGobletTM cells were pre-incubated for 4 hours with Utipro® (0, 5, 10 187 
mg/mL). After Utipro® treatment, cells were infected with E. coli (1×107 cfu/mL) 188 
and incubated for 1h. Later, the cell monolayers were washed three times with 189 
sterile PBS and treated with 100 mM Penicillin-Streptomycin for 10 minutes. 190 
Finally, cell monolayers were washed 3 times with sterile PBS and exposed to 191 
1% Triton X-100 for 10 minutes to produce cell lysates and release the 192 
internalized bacteria. Quantitative values of intracellular bacteria were obtained 193 
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by bacterial counting in cell lysates and the results were Log10-transformed 194 




2.7 Anti-adherence effects of xyloglucan and gelatin 199 
In a similar manner, we evaluated the protective effect exerted by the film 200 
forming agent xyloglucan and gelatin. After microbial adsorption of E. coli 201 
(ATCC 8739) and without washing, 5 mg/mL of xyloglucan and gelatin (PL422 202 
and PL423 powder dissolved in bicarbonate solution) were added onto the cell-203 
monolayers, in triplicates. Cells were incubated for different period of time (1h, 204 
4h and 24h) at 37ºC and 5% of CO2. In this experiment, duplicate wells of 205 
untreated plus bicarbonate solution cell-monolayers were used as negative 206 
controls. Bacterial count was analysed by Tali™ Image Cytometer. Changes of 207 
those parameters were analysed by comparing the values before and after E. 208 
coli inoculation and after the addition of xyloglucan and gelatin (1h, 4h and 24 h 209 
of treatment).  210 
 211 
2.7. Statistical analysis 212 
A descriptive analysis of quantitative data was performed. Mean and 213 
standard deviation of TEER, LY (%) and bacterial count (Log10) values were 214 
calculated from Utipro®-treated and untreated cell monolayers. 215 
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 216 
3. RESULTS 217 
3.1. Cytotoxicity 218 
Utipro® treatment of Caco-2 cells for 4h showed no cytotoxic effects. Cell 219 
viabilities were greater than 88% using Utipro® powder (88.6%) or Utipro® 220 
dissolved in bicarbonate (88.5%) (Figure 1). 221 
3.2. Protective properties of Utipro® on cell monolayers 222 
CacoGobletTM cell monolayers treated with Utipro® for 4h showed higher 223 
TEER values compared to untreated cells. Mean±SD (Ω × cm2) TEER values 224 
were 66.83±0.288 and 71.33±0.288 with Utipro® 5 and 10 mg/mL, respectively, 225 
while the mean±SD (Ω × cm2) TEER value in untreated cells was 59.17±0.00 226 
(Figure 2). 227 
3.3. Protective properties of Utipro® to preserve the paracellular flux 228 
Utipro® did not alter cell permeability within the mucosal barrier model. 229 
Utipro® maintained the paracellular flux between AP and BL compartments of 230 
treated cells independently of the concentration assayed. Mean±SD (%) LY 231 
flux values were 10.64±0.51 (1.5 mg/mL Utipro®), 8.70±1.37 (2.5 mg/mL 232 
Utipro®) and 9.90±0.25 (5 mg/mL Utipro®) (Figure 3), similar to LY flux values 233 
obtained in untreated cells (10.08±0.65%). 234 
3.4. Protective properties of Utipro® against E. coli invasion of the 235 
intestinal mucosa 236 
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Utipro® treatment (4h) in CacoGobletTM cell monolayers reduced the 237 
intracellular invasion of E. coli compared with untreated cells. Utipro® 5 mg/mL 238 
reduced the intracellular invasion of E. coli by a mean±SD (Log10) of 0.9±0.06 239 
(from 2.1×104 to 2.4×103 average bacteria total count/well); Utipro® 10 mg/mL 240 
reduced the intracellular invasion of E. coli by a mean±SD (Log10 of bacteria 241 
total count/well) of 2.1±0.56 (from 2.1×104 to 1.2×102 average bacteria total 242 
count/well) (Figure 4). 243 
3.5 Anti-adherence effects of xyloglucan and gelatin 244 
E. coli was retained in the apical supernatant and in the homogenate mucus 245 
(> 6 Log10). After treatment of cell-monolayers with xyloglucan and gelatin, 246 
bacteria were equally distributed in apical and homogenate mucus 247 
compartments at all time points of treatment. Treatment with xyloglucan and 248 
gelatine produced a decrease in the number of E. coli cells adhered, particularly 249 






Utipro® has recently been approved as an oral medical device to prevent 256 
UTIs. Its components are well known natural products habitually used in food 257 
and drinks, beingwell tolerated. The main ingredient of Utipro® is gelatin-258 
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xyloglucan. Xyloglucan, from T. indica seeds, is a soluble hemicellulose which, 259 
combined with gelatin-A, forms an innocuous biopolymer that exerts a physical 260 
barrier against intestinal E. coli invasion and gut alterations in animals [19]. 261 
In the context of UTIs, several studies indicate the fecal tract flora as a 262 
potential reservoir of uropathogenic E. coli B2 that could increase the risk of 263 
urinary tract colonization [21−23]. The persistence of this uropathogenic group 264 
in the lower intestinal tract is supported by the activation of several virulence-265 
associated genes that express virulence factors such as adhesins (fimbriae and 266 
p-pili), toxins, polysaccharide capsules and siderophores, which can be 267 
modulated by environmental conditions, such as changes in pH and osmolarity 268 
[21−23]. The expression of a broad variety of virulence-associated genes 269 
provides advantages for the colonization of different microhabitats [23]. 270 
In this study, we aimed to provide basic evidence that Utipro® exerts a 271 
protective effect against E. coli adhesion and invasion in intestinal epithelial 272 
cells. We used established human intestinal epithelial cell models that mimic 273 
intestinal mucosa [24,25], and well-known methods, such as TEER and LY, to 274 
evaluate the preservation of cellular tight junctions [26,27]. 275 
The aim of this study was to demonstrate the basis of the mechanism of action 276 
of a product intended to prevent urinary infections. We consider that the 277 
observed protective effects (anti-adhesive and anti-invasive properties) of 278 
Utipro® on intestinal epithelial cells is the first step to avoid urinary colonization, 279 
according to the fecal-perineal-urethral hypothesis [20]. Due to the preventive 280 
nature of the product, we consider that this step at intestinal level is of great 281 
importance for the mechanism of action of Utipro®.  282 
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 283 
In further studies, we will assess the effects of Utipro® in in vitro and in vivo 284 
models of the UTIs using a wide panel of uropathogenic strains and also in 285 
randomized clinical studies in subjects susceptible to have UTIs. 286 
We used the strain E. coli ATCC 8739 since it was used in previous in vitro and 287 
in vivo studies performed by our company with Utipro® and with the film forming 288 
agents xyloglucan and gelatin. As already demonstrated in our studies, it has 289 
the capacity to adhere and invade intestinal epithelial cells, thus making it 290 
suitable for this type of assays. This is in line with its faecal origin 291 
(http://www.lgcstandards-atcc.org/Products/All/8739-MINI-PACK.aspx).  292 
 293 
For the first time, we have demonstrated that Utipro® prevents the 294 
intracellular invasion of E. coli by 2 Log10 in an intestinal epithelial cell model, 295 
thus reducing the development of E. coli reservoirs. We consider that the anti-296 
adhesive and anti-invasive properties of xyloglucan and gelatin allow the 297 
expulsion with the faeces of the bacteria embedded in the protective film, thus 298 
avoiding bacterial colonization of the perianal region and the urinary tract. 299 
 300 
Further clinical studies assessing the effect of Utipro® in patients with the first 301 
symptoms of UTIs willconfirm these results. 302 
We consider that the mechanism of action of Utipro® is non-pharmacological, 303 
since Utipro® forms a physical barrier on the mucus of intestinal epithelial cells 304 
that increases the resistance of cell tight junctions and protects intestinal cells 305 
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against the adherence of E. coli. The xyloglucan-gelatin biopolymer prevents 306 
the binding of fimbriae and p-pili to cell oligosaccharides and protects tight 307 
junctions from bacterial translocation, indicating a clear effect of resistance to 308 
bacterial invasion and the potential development of quiescent reservoirs of E. 309 
coli in the intestinal epithelium model. In previous in vivo studies we have also 310 
demonstrated the anti-secretory effects of xyloglucan and gelatine after 311 
treatment with LPS and cholera toxin, thus demonstrating the protective effects 312 
in a model of tight junctions alterations [19]. These results are also in line with 313 
those obtained in clinical trials in patients with diarrhea, in which the 314 
administration of xyloglucan for 3 days resulted in rapid improvements in 315 
diarrheal symptoms (measured as type 6 and 7 Bristol scale stools) and a 316 
reduction in the percentage of patients with nausea, vomiting and abdominal 317 
pain [18]. The beneficial effects of film forming agents have also been 318 
demonstrated in patients with irritable bowel syndrome [28]. 319 
We consider that the recommended posology assures the required time to exert 320 
the preventive action: the device is to be taken orally as 2 capsules per day for 321 
5 days in the case of patients who develop the first urinary discomfort 322 
symptoms, and as 1 capsule per day for at least 15 consecutive days per 323 
month, for the prevention of recurrence (if necessary, the product can be taken 324 
for repeated cycles) (Utipro Leaflet, Novintethical Pharma, SA).  325 
 326 
In conclusion, results of our study indicate that Utipro® creates a protective 327 
physical barrier on intestinal epithelial cells in vitro, which can reduce the 328 
settling of E. coli reservoirs. These results constitute the first step for the 329 
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demonstration of the efficacy of Utipro® to prevent UTIs. Futher research is 330 
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EXECUTIVE SUMMARY 344 
• Utipro®, a non-pharmacological oral medical device which was approved 345 
recently for the prevention of UTIs, contains gelatin-xyloglucan (a natural 346 
hemicellulose) as the main ingredient, along with other plant extracts. 347 
• Xyloglucan belongs to a new class of products, defined as “mucosal 348 
protectors”, which form a bio-protective film, restoring the physiological 349 
functions of the intestinal walls. 350 
• This in vitro study evaluated whether Utipro® protects intestinal epithelial 351 
cells from Escherichia coli adherence and intracellular invasion. 352 
• Utipro® was non-cytotoxic. 353 
• Utipro® 5 and 10 mg/mL protected cell tight junctions (mean±SD 354 
transepithelial electrical resistance [Ω×cm2] 66.83±0.29 and 71.33±0.29, 355 
respectively). 356 
• Utipro® 5 and 10 mg/mL protected cells from E. coli intracellular invasion 357 
(mean±SD reductions in total bacteria counts [Log10] 0.9±0.06 and 358 
2.1±0.56, respectively) and bacterial adherence. 359 
• In vitro, Utipro® created a protective physical barrier on intestinal 360 
epithelial cells, which is able to reduce the settling of E. coli reservoirs. 361 
  362 
 18 
REFERENCES 363 
1.  Magliano E, Grazioli V, Deflorio L et al. Gender and age-dependent 364 
etiology of community-acquired urinary tract infections. Scientific World 365 
Journal 2012, 349597 (2012). 366 
2.  Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, 367 
and economic costs. Am. J. Med. 113(Suppl 1A), 5S−13S (2002). 368 
3.  Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of 369 
urinary tract infections in the outpatient setting: a review. JAMA 312(16), 370 
1677−1684 (2014). 371 
 * A recent review of the diagnosis and management of urinary tract 372 
infections 373 
4.  Bermingham SL, Ashe JF. Systematic review of the impact of urinary 374 
tract infections on health-related quality of life. BJU Int. 110(11 Pt C), 375 
E830−E836 (2012). 376 
5.  Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women's quality of life is 377 
decreased by acute cystitis and antibiotic adverse effects associated with 378 
treatment. Health Qual. Life Outcomes 3, 45 (2005). 379 
6.  Abrahamian FM, Krishnadasan A, Mower WR, Moran GJ, Coker JR, 380 
Talan DA. The association of antimicrobial resistance with cure and 381 
quality of life among women with acute uncomplicated cystitis. Infection 382 
39(6), 507−514 (2011). 383 
 19 
7.  Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract 384 
infection: the "costs of resignation". Clin. Drug Investig. 33(4), 255−261 385 
(2013). 386 
8.  Minardi D, d'Anzeo G, Cantoro D, Conti A, Muzzonigro G. Urinary tract 387 
infections in women: etiology and treatment options. Int. J. Gen. Med. 4, 388 
333−343 (2011). 389 
9.  Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli 390 
isolates are dominated by strains of phylogenetic group B2. J. Clin. 391 
Microbiol. 40(11), 3951−3955 (2002). 392 
10. Moreno E, Andreu A, Pigrau C, Kuskowski MA, Johnson JR, Prats G. 393 
Relationship between Escherichia coli strains causing acute cystitis in 394 
women and the fecal E. coli population of the host. J. Clin. Microbiol. 395 
46(8), 2529−2534 (2008). 396 
 * Findings of this cross-section study in women with acute uncomplicated 397 
cystitis have shown that phylogenetic group B2 status and/or associated 398 
virulence factors may promote fecal abundance and pauciclonality, 399 
thereby contributing to upstream steps in UTI pathogenesis.  400 
11. Nielsen KL, Dynesen P, Larsen P, Frimodt-Møller N. Faecal Escherichia 401 
coli from patients with E. coli urinary tract infection and healthy controls 402 
who have never had a urinary tract infection. J. Med. Microbiol. 63(Pt 4), 403 
582−589 (2014). 404 
12. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N. 405 
Engl. J. Med. 366(11), 1028−1037 (2012). 406 
 20 
 * A clinically-oriented review of uncomplicated urinary tract 407 
infections 408 
13. Bader MS, Hawboldt J, Brooks A. Management of complicated urinary 409 
tract infections in the era of antimicrobial resistance. Postgrad. Med. 410 
122(6), 7−15 (2010). 411 
14. Howell AB. Cranberry proanthocyanidins and the maintenance of urinary 412 
tract health. Crit Rev Food Sci Nutr.  42(3 Suppl):273-8 (2002).  413 
15. Howell AB, Botto H, Combescure C, et al. Dosage effect on 414 
uropathogenic Escherichia coli anti-adhesion activity in urine following 415 
consumption of cranberry powder standardized for proanthocyanidin 416 
content: a multicentric randomized double blind study. BMC Infect 417 
Dis. 10:94 (2010). 418 
16. Gupta A, Dwivedi M, Mahdi AA, Nagana Gowda GA, Khetrapal 419 
CL, Bhandari M. Inhibition of adherence of multi-drug resistant E. coli by 420 
proanthocyanidin. Urol Res. 40(2):143-50.  421 
17. Chisholm AH. Probiotics in preventing recurrent urinary tract infections in 422 
women: a literature review. Urol. Nurs. 35(1), 18−21 (2015). 423 
18. Gnessi L, Bacarea V, Marusteri M, Piqué N. Xyloglucan for the treatment 424 
of acute diarrhea: results of a randomized, controlled, open-label, parallel 425 
group, multicentre, national clinical trial. BMC Gastroenterol. 15(1),153 426 
(2015). 427 
 ** Study showing that the film forming agent xyloglucan is a fast, 428 
efficacious and safe option for the treatment of acute diarrhea 429 
 21 
19. Bueno L, Theodorou V, Sekkal S. Xyloglucan: a new agent to protect the 430 
intestinal mucosa and to prevent bacterially-mediated alteration of tight 431 
junction permeability [Abstract P1675]. United European Gastroenterol. 432 
J. 2(1 Suppl), A591 (2014). 433 
20. Yamamoto S, Tsukamoto T, Terai A, Kurazono H, Takeda Y, Yoshida O. 434 
Genetic evidence supporting the fecal-perineal-urethral hypothesis in 435 
cystitis caused by Escherichia coli. J. Urol. 157(3), 1127−1129 (1997). 436 
21. Katouli, M. Population structure of gut Escherichia coli and its role in 437 
development of extra-intestinal infections. Iran. J. Microbiol. 2(2), 59–72 438 
(2010). 439 
22. Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of 440 
commensal Escherichia coli. Nat. Rev. Microbiol. 8(3), 207−217 (2010). 441 
23. Frömmel U, Lehmann W, Rödiger S et al. Adhesion of human and animal 442 
Escherichia coli strains in association with their virulence-associated 443 
genes and phylogenetic origins. Appl. Environ. Microbiol. 79(19), 444 
5814−5829 (2013). 445 
24. Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, 446 
Langguth P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: 447 
permeabilities via diffusion, inside- and outside-directed carrier-mediated 448 
transport. J. Pharm. Sci. 89(1), 63−75 (2000). 449 
25. Pontier C, Pachot J, Botham R, Lenfant B, Arnaud P. HT29-MTX and 450 
Caco-2/TC7 monolayers as predictive models for human intestinal 451 
 22 
absorption: role of the mucus layer. J. Pharm. Sci. 90(10), 1608−1619 452 
(2001). 453 
26. Stewart WW. Functional connections between cells as revealed by dye-454 
coupling with a highly fluorescent naphthalimide tracer. Cell 14(3), 455 
741−759 (1978). 456 
27. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial 457 
cells from the effects of infection with enteroinvasive Escherichia coli 458 
(EIEC). Gut 52(7), 988−997 (2003). 459 
28. Alexea O, Bacarea V, Piqué N. The combination of oligo-and 460 
polysaccharides and reticulated protein for the control of symptoms in 461 
patients with irritable bowel síndrome: Results of a randomized, placebo-462 
controlled, double-blind, parallel group, multicentre clinical trial. UEG 463 
journal (2005). DOI: 10.1177/2050640615615050. 464 
  465 
 23 
FIGURE LEGENDS 466 
Figure 1. Evaluation of cell viability (%) after 4h of treatment with Utipro® (10 467 
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 474 
Figure 2. Protective properties of Utipro® to preserve tight junctions among 475 
CacoGobletTM cells. TEER values (mean±SD, Ω × cm2) increased with Utipro® 476 
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 482 
Figure 3. Protective properties of Utipro® to preserve the paracellular flux 483 
between the apical and basolateral compartments of CacoGobletTM cells. 484 
Utipro® did not alter the cell permeability within the mucosal barrier model. LY 485 
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 491 
Figure 4. Evaluation of preventive and anti-absorptive properties of Utipro® 492 
against E. coli invasion. Four hours of preventive treatment with Utipro® (5 and 493 
10 mg/mL) reduced microbial growth (mean bacterial total count/well) >0.9 494 
Log10 compared to untreated cells (0 mg/mL). 495 
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